Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2024)
Allogene Therapeutics (ALLO) reported EBITDA Margin of 315927.27% for Q1 2024, up 1437939.0% on a YoY basis from N/an in Q2 2023, and up 22.05% sequentially from 405280.95% in Q4 2023.
Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2024) Analysis & Trends
Allogene Therapeutics (ALLO) has 4 years of EBITDA Margin data on file, last reported at 315927.27% in Q1 2024.
- For the quarter ending Q1 2024, EBITDA Margin rose 1437939.0% year-over-year to 315927.27%; the trailing twelve-month figure through Dec 2024 stood at 1241813.64% (down 89682732.0% YoY), and the FY2024 full-year result was 1241813.64%, down 89682732.0% from the prior year.
- EBITDA Margin advanced to 315927.27% in Q1 2024, from 405280.95% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2.26% in Q4 2021 to a low of 405280.95% in Q4 2023.
- A 4-year average of 232707.56% and a median of 286345.45% in 2023 frame the typical range for EBITDA Margin.
- Peak annual rise in EBITDA Margin reached 4171705 bps in 2022, while the deepest fall reached 37075226 bps in 2022.
- Tracing ALLO's EBITDA Margin over 4 years: stood at 2.26% in 2021, then sank by 16431036 bps to 370750.0% in 2022, then retreated by 9 bps to 405280.95% in 2023, then increased by 22 bps to 315927.27% in 2024.
- Business Quant data shows ALLO's EBITDA Margin at 315927.27% in Q1 2024, 405280.95% in Q4 2023, and 286345.45% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -315,927.27% |
| Dec 31, 2023 | -405,280.95% |
| Sep 30, 2023 | -286,345.45% |
| Jun 30, 2023 | -366,090.91% |
| Mar 31, 2023 | -330,306.67% |
| Dec 31, 2022 | -370,750.00% |
| Sep 30, 2022 | -305,596.30% |
| Jun 30, 2022 | -119,712.50% |
| Mar 31, 2022 | -205,164.10% |
| Dec 31, 2021 | 2.26% |
| Sep 30, 2021 | -158,510.20% |
| Jun 30, 2021 | -161,429.55% |
| Mar 31, 2021 | -86.58% |